Skip to main content
. Author manuscript; available in PMC: 2023 Feb 20.
Published in final edited form as: Clin Cancer Res. 2022 Jun 13;28(12):2567–2578. doi: 10.1158/1078-0432.CCR-21-4064

Figure 2. Circulating Immune Cell Subsets Comparing Newly Diagnosed and Recurrent Patients.

Figure 2.

Measurement of baseline immune cell subsets detected by flow cytometry among newly diagnosed patients (cohort A; open bars and symbols) compared to bevacizumab-naïve, recurrent patients (cohorts B, B2 and B3; gray bars and symbols) including major immune cell subsets (panel A), and CD4+ and CD8+ T cells distinguished by memory or naïve (panel B), activation (panel C) or proliferation (panel D) markers. Asterisks indicate p<0.01 by Mann-Whitney U test comparing cohort A to cohorts B, B2 and B3. Panel E: Change in baseline CD8+Ki67+ T cells at day 15 for newly diagnosed (cohort A, open symbols) and bevacizumab-naïve, recurrent patients (cohorts B, B2 and B3, gray symbols) on baseline dexamethasone use (right side triangles) compared to those not on dexamethasone (left side circles). Bars indicate median value and error bars denote 25th and 75th percentiles. Asterisk indicates p ≤ 0.01. P value was determined by Wilcoxon Signed Rank test.